Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/apt.70490 http://scihub22266oqcxt.onion/10.1111/apt.70490 41390946!?!41390946 Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=41390946&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Aliment+Pharmacol+Ther 2025 ; ? (?): ? Nephropedia Template TP {{tp|p=41390946|t=2025. Meta-Analysis: High anti-HBs Titers are Associated with Significantly Reduced Risk of Hepatitis B Virus Reactivation During Rituximab Treatment |pdf=|usr=}}{{41390946}} gab.com Text Meta-Analysis: High anti-HBs Titers are Associated with Significantly Reduced Risk of Hepatitis B Virus Reactivation During Rituximab Treatment JO: Aliment Pharmacol Ther http://www.kidney.de/pget.php?&tw=1&pmid=41390946 #FOAvip BACKGROUND: Hepatitis B virus (HBV) reactivation is a serious complication in patients receiving chronic immunosuppression. Anti-CD20 agents such as Rituximab are considered high risk for HBV reactivation (> 10%); therefore, antiviral prophylaxis is recommended for all anti-HBc positive patients. Some studies have suggested that patients with resolved HBV infection and higher hepatitis B surface antibody (anti-HBs) titer have a higher level of protection against reactivation. AIM: The purpose of this study was to systematically review the role of anti-HBs titer on HBV reactivation in patients on rituximab while not on antiviral therapy/prophylaxis. METHODS: We systematically reviewed all studies that discussed HBV reactivation in patients on rituximab therapy with resolved HBV infection, defined as HBsAg negative and anti-HBc positive, which discussed anti-HBs titer. The search was conducted in PubMed, Embase via Elsevier, Scopus, and Cochrane CENTRAL inclusive July 2025. We evaluated the incidence of HBV reactivation from cohort studies that described anti-HBs categorically based on anti-HBs titer: 'negative' (titer < 10 iU/L), '10-100 iU/L', or '> 100 iU/L'. Meta-analysis statistics describe the proportion and risk difference for different anti-HBs levels. RESULTS: The overall reactivation rate was 12.6%. There was a significant difference in HBV reactivation depending on titer: anti-HBs negative 27.3% (51/195) (20.0%-36.0%), titer < 100 iU/L 13.8% (47/379) (8.8%-20.8%), and titer > 100 iU/L 3.5% (8/339) (1.8%-6.9%). CONCLUSIONS: Those with anti-HBs titer > 100 iU/L can be considered lower risk for HBV reactivation and may not require antiviral therapy, but monitoring with initiation of antiviral therapy if titer falls below 100 iU/L. Twit Text FOAVip Meta-Analysis: High anti-HBs Titers are Associated with Significantly Reduced Risk of Hepatitis B Virus Reactivation During Rituximab Treatment ????Aliment Pharmacol Ther http://www.kidney.de/pget.php?&tw=1&pmid=41390946 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=41390946 #FOAvip English Wikipedia <ref>{{Cite pmid|41390946}}</ref> Meta-Analysis: High anti-HBs Titers are Associated with Significantly Reduced Risk of Hepatitis B Virus Reactivation During Rituximab Treatment #MMPMID41390946 Poola S; Kratzer M; Sewell K; Yang Z; Tillmann HL Aliment Pharmacol Ther 2025[Dec]; ? (?): ? PMID41390946show ga BACKGROUND: Hepatitis B virus (HBV) reactivation is a serious complication in patients receiving chronic immunosuppression. Anti-CD20 agents such as Rituximab are considered high risk for HBV reactivation (> 10%); therefore, antiviral prophylaxis is recommended for all anti-HBc positive patients. Some studies have suggested that patients with resolved HBV infection and higher hepatitis B surface antibody (anti-HBs) titer have a higher level of protection against reactivation. AIM: The purpose of this study was to systematically review the role of anti-HBs titer on HBV reactivation in patients on rituximab while not on antiviral therapy/prophylaxis. METHODS: We systematically reviewed all studies that discussed HBV reactivation in patients on rituximab therapy with resolved HBV infection, defined as HBsAg negative and anti-HBc positive, which discussed anti-HBs titer. The search was conducted in PubMed, Embase via Elsevier, Scopus, and Cochrane CENTRAL inclusive July 2025. We evaluated the incidence of HBV reactivation from cohort studies that described anti-HBs categorically based on anti-HBs titer: 'negative' (titer < 10 iU/L), '10-100 iU/L', or '> 100 iU/L'. Meta-analysis statistics describe the proportion and risk difference for different anti-HBs levels. RESULTS: The overall reactivation rate was 12.6%. There was a significant difference in HBV reactivation depending on titer: anti-HBs negative 27.3% (51/195) (20.0%-36.0%), titer < 100 iU/L 13.8% (47/379) (8.8%-20.8%), and titer > 100 iU/L 3.5% (8/339) (1.8%-6.9%). CONCLUSIONS: Those with anti-HBs titer > 100 iU/L can be considered lower risk for HBV reactivation and may not require antiviral therapy, but monitoring with initiation of antiviral therapy if titer falls below 100 iU/L. ?Meta-Analysis: High anti-HBs Titers are Associated with Significantly (epmc).pdf DeepDyve Pubget Overpricing